Government ❯Regulatory Agencies ❯FDA

Drug Approval

Mifepristone Psychedelic Drugs Regulations Safety Monitoring Supply Chain Management Opioid Test FDA Regulations Medicine Regulation Mifepristone Regulations Legal Challenges Safety Evaluation Clinical Trials Public Health MDMA

FDA Posts Advertising Crackdown Letters, Targets Hims & Hers Over Compounded Weight-Loss Claims

The move follows a presidential order on truthful drug ads, setting a 15‑working‑day window for corrective plans under threat of enforcement.

New Study Reveals Abortion Pill Complication Rate 22 Times Higher Than FDA Estimate

Novavax Shares Fall as Revenue Forecast Slashed Again

Trump Hints at Possible Abortion Pill Ban

FDA Reviews MDMA-Assisted Therapy for PTSD as Congress Pushes Psychedelic Research